Ritter Pharmaceuticals appoints new CMO

Ritter Pharmaceuticals has appointed AnnKatrin Petersen-Jappelli as chief medical officer.

Ritter is currently developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases.

Michael Step, CEO of Ritter Pharmaceuticals, said: “The additions of Dr Petersen-Jappelli further strengthens Ritter Pharmaceuticals' management with a leader who has significant experience in both the biotech and pharmaceutical industries, with a focus on treating gastrointestinal diseases.

Petersen-Jappelli joins Ritter having spent over 25 years in the pharmaceutical and biotechnology industry. Before this she served at Santarus as scientific research and clinical development leader of a phase III program for traveler's diarrhoea.

She said: “Joining Ritter Pharmaceuticals is an exciting opportunity to be part of a unique and innovative company that is working to treat gastrointestinal disease through the modulation of the gut microbiome.

“I believe my experience in product development coupled with my research capabilities will be a great combination for this role and I look forward to working with the team as we advance our science, build our product portfolio, and bring therapeutics to market that have the potential to provide significant relief to patients suffering from gastrointestinal diseases.”